Tuberculosis and malaria are among the deadliest infectious diseases worldwide and are increasingly spreading, not least due to climate change. In both cases, antimicrobial resistance renders established active substances ineffective. To ensure that effective drugs are still available in the future, researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) are working together with Evotec, a leading company for drug research and development, on resistance-breaking anti-infectives based on natural products. The research project of the team led by Prof. Rolf Müller now receives 3.1 million euros in funding from the Bill & Melinda Gates Foundation. In addition, the HIPS has been accepted as a member of the renowned "Tuberculosis Drug Accelerator".
↧